MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1997-03

AUTHORS

Joann L. Ater, Jan van Eys, Shiao Y. Woo, Bartlett Moore III, Donna R. Copeland, Janet Bruner

ABSTRACT

Infants and young children who have brain tumors have a poor rateof survival and high treatment associated morbidity. A trial of mechlorethamine, vincristine (oncovin), procarbazine, and prednisone(MOPP) was performed to test the hypothesis that replacingradiotherapy with chemotherapy would improve survival and decreaselong term morbidity of infants who have brain tumors. Between 1976 and1988, 17 consecutive children less than 36 months old when diagnosed with medulloblastoma or ependymoma were treatedwith MOPP chemotherapy as primary therapy following surgical excision or biopsy of the tumor. Radiotherapy was reserved for recurrent disease. Ten of 17 children have survived without evidence of disease: medulloblastoma, eight of 12 with median survivaltime of 10.6 years (range, 6.2 to 15.2 yrs); and ependymoma, 2of 5 (at 13.0 and 16.0 yrs). Four of the 10 children with medulloblastomaand ependymoma who relapsed are now disease free at 7.5, 11.7, 12.2 and 13.5 yrs post relapse after receiving salvagetherapy with cisplatin (n = 1) or irradiation (n = 3). All relapsesoccurred within 26 months of diagnosis. Data on growth demonstrated heightless than the 5th percentile in all children who received cranial irradiation compared to 25 to 95th percentile for nonirradiated children. Intellectual ability for the groupwho did not require radiation was within normal range (mean IQ 100.1) and stable across annual assessments. Those who required radiation hadlower IQs which continued to decline over time (mean IQ 85 at mean age of 5.8 years, declining to 63 at 10 years).In young children with brain tumors, primary chemotherapy with MOPP, omitting radiotherapy, provides improved neurodevelopmental outcome and survival. More... »

PAGES

243-252

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1023/a:1005744527443

DOI

http://dx.doi.org/10.1023/a:1005744527443

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1000646940

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9049886


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cerebellar Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ependymoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Intelligence Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mechlorethamine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medulloblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Procarbazine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The Departments of Pediatrics, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "The Departments of Pediatrics, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ater", 
        "givenName": "Joann L.", 
        "id": "sg:person.01110645104.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110645104.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Departments of Pediatrics, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "The Departments of Pediatrics, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eys", 
        "givenName": "Jan van", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Clinical Radiotherapy, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Clinical Radiotherapy, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Woo", 
        "givenName": "Shiao Y.", 
        "id": "sg:person.012415720762.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012415720762.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Departments of Pediatrics, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "The Departments of Pediatrics, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "III", 
        "givenName": "Bartlett Moore", 
        "id": "sg:person.015203521537.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015203521537.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Departments of Pediatrics, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "The Departments of Pediatrics, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Copeland", 
        "givenName": "Donna R.", 
        "id": "sg:person.0667371236.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667371236.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bruner", 
        "givenName": "Janet", 
        "id": "sg:person.013375073077.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00165184", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022244908", 
          "https://doi.org/10.1007/bf00165184"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1997-03", 
    "datePublishedReg": "1997-03-01", 
    "description": "Infants and young children who have brain tumors have a poor rateof survival and high treatment associated morbidity. A trial of mechlorethamine, vincristine (oncovin), procarbazine, and prednisone(MOPP) was performed to test the hypothesis that replacingradiotherapy with chemotherapy would improve survival and decreaselong term morbidity of infants who have brain tumors. Between 1976 and1988, 17 consecutive children less than 36 months old when diagnosed with medulloblastoma or ependymoma were treatedwith MOPP chemotherapy as primary therapy following surgical excision or biopsy of the tumor. Radiotherapy was reserved for recurrent disease. Ten of 17 children have survived without evidence of disease: medulloblastoma, eight of 12 with median survivaltime of 10.6 years (range, 6.2 to 15.2 yrs); and ependymoma, 2of 5 (at 13.0 and 16.0 yrs). Four of the 10 children with medulloblastomaand ependymoma who relapsed are now disease free at 7.5, 11.7, 12.2 and 13.5 yrs post relapse after receiving salvagetherapy with cisplatin (n = 1) or irradiation (n = 3). All relapsesoccurred within 26 months of diagnosis. Data on growth demonstrated heightless than the 5th percentile in all children who received cranial irradiation compared to 25 to 95th percentile for nonirradiated children. Intellectual ability for the groupwho did not require radiation was within normal range (mean IQ 100.1) and stable across annual assessments. Those who required radiation hadlower IQs which continued to decline over time (mean IQ 85 at mean age of 5.8 years, declining to 63 at 10 years).In young children with brain tumors, primary chemotherapy with MOPP, omitting radiotherapy, provides improved neurodevelopmental outcome and survival.", 
    "genre": "article", 
    "id": "sg:pub.10.1023/a:1005744527443", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2467142", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "keywords": [
      "brain tumors", 
      "MOPP chemotherapy", 
      "young children", 
      "evidence of disease", 
      "months of diagnosis", 
      "postsurgical therapy", 
      "primary therapy", 
      "cranial irradiation", 
      "primary chemotherapy", 
      "term morbidity", 
      "recurrent disease", 
      "consecutive children", 
      "neurodevelopmental outcome", 
      "surgical excision", 
      "normal range", 
      "chemotherapy", 
      "tumors", 
      "ependymoma", 
      "infants", 
      "disease", 
      "morbidity", 
      "children", 
      "radiotherapy", 
      "survival", 
      "therapy", 
      "medulloblastoma", 
      "annual assessments", 
      "months", 
      "percentile", 
      "MOPP", 
      "relapse", 
      "biopsy", 
      "vincristine", 
      "high treatment", 
      "excision", 
      "diagnosis", 
      "trials", 
      "cisplatin", 
      "mechlorethamine", 
      "outcomes", 
      "treatment", 
      "intellectual ability", 
      "years", 
      "assessment", 
      "evidence", 
      "irradiation", 
      "IQ", 
      "hypothesis", 
      "ability", 
      "data", 
      "time", 
      "growth", 
      "radiation", 
      "range", 
      "poor rateof survival", 
      "rateof survival", 
      "trial of mechlorethamine", 
      "decreaselong term morbidity", 
      "and1988", 
      "median survivaltime", 
      "survivaltime", 
      "medulloblastomaand ependymoma", 
      "yrs post relapse", 
      "post relapse", 
      "salvagetherapy", 
      "heightless", 
      "groupwho", 
      "radiation hadlower IQs", 
      "hadlower IQs", 
      "primary postsurgical therapy"
    ], 
    "name": "MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children", 
    "pagination": "243-252", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1000646940"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1023/a:1005744527443"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9049886"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1023/a:1005744527443", 
      "https://app.dimensions.ai/details/publication/pub.1000646940"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_289.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1023/a:1005744527443"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1023/a:1005744527443'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1023/a:1005744527443'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1023/a:1005744527443'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1023/a:1005744527443'


 

This table displays all metadata directly associated to this object as RDF triples.

245 TRIPLES      22 PREDICATES      115 URIs      106 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1023/a:1005744527443 schema:about N08207dd13f1240ea95454e4b42780d3d
2 N27f45763f5a44a24a954903078b971cd
3 N40c608e5cb7444a7a2eec144197d2770
4 N44c81835dbc94bd7a48eab57d1d517f9
5 N61d238067e0a47da9548584ab32d8206
6 N6331d787a594495a8fd69a47da63537b
7 N67bc444c5a6d441f8f643b9a7ee7d54a
8 N8226d466276540f9ba47a65a30f675dc
9 Na456f8a2ea2e4608bf3e8e62b70c72f6
10 Naf6e47ed61f84908b073e3ebf0842c60
11 Nba80a5f929474713bbb381781209fa08
12 Nc0f3ab3a603d49c9a7dde0d02df2ee19
13 Nddd64aabe6854bb18293147c5fd96e78
14 Ndfe2d757403d435b81bdc5d67c5b3c8e
15 Ne45d24f62fcc46519afae80e86ca5fbf
16 Ne6db28a0fa3e4da3bc5caa2341b65f72
17 Nf8ef26cf59b24a84a3c5cd734b506714
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Na8998ec9fdb6495b819e432f8ec12c00
21 schema:citation sg:pub.10.1007/bf00165184
22 schema:datePublished 1997-03
23 schema:datePublishedReg 1997-03-01
24 schema:description Infants and young children who have brain tumors have a poor rateof survival and high treatment associated morbidity. A trial of mechlorethamine, vincristine (oncovin), procarbazine, and prednisone(MOPP) was performed to test the hypothesis that replacingradiotherapy with chemotherapy would improve survival and decreaselong term morbidity of infants who have brain tumors. Between 1976 and1988, 17 consecutive children less than 36 months old when diagnosed with medulloblastoma or ependymoma were treatedwith MOPP chemotherapy as primary therapy following surgical excision or biopsy of the tumor. Radiotherapy was reserved for recurrent disease. Ten of 17 children have survived without evidence of disease: medulloblastoma, eight of 12 with median survivaltime of 10.6 years (range, 6.2 to 15.2 yrs); and ependymoma, 2of 5 (at 13.0 and 16.0 yrs). Four of the 10 children with medulloblastomaand ependymoma who relapsed are now disease free at 7.5, 11.7, 12.2 and 13.5 yrs post relapse after receiving salvagetherapy with cisplatin (n = 1) or irradiation (n = 3). All relapsesoccurred within 26 months of diagnosis. Data on growth demonstrated heightless than the 5th percentile in all children who received cranial irradiation compared to 25 to 95th percentile for nonirradiated children. Intellectual ability for the groupwho did not require radiation was within normal range (mean IQ 100.1) and stable across annual assessments. Those who required radiation hadlower IQs which continued to decline over time (mean IQ 85 at mean age of 5.8 years, declining to 63 at 10 years).In young children with brain tumors, primary chemotherapy with MOPP, omitting radiotherapy, provides improved neurodevelopmental outcome and survival.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree false
28 schema:isPartOf N2ee6cab87bc94817b64f0030a636703b
29 Ne7389cc13df044bcaa49e58a2dce6a2b
30 sg:journal.1094205
31 schema:keywords IQ
32 MOPP
33 MOPP chemotherapy
34 ability
35 and1988
36 annual assessments
37 assessment
38 biopsy
39 brain tumors
40 chemotherapy
41 children
42 cisplatin
43 consecutive children
44 cranial irradiation
45 data
46 decreaselong term morbidity
47 diagnosis
48 disease
49 ependymoma
50 evidence
51 evidence of disease
52 excision
53 groupwho
54 growth
55 hadlower IQs
56 heightless
57 high treatment
58 hypothesis
59 infants
60 intellectual ability
61 irradiation
62 mechlorethamine
63 median survivaltime
64 medulloblastoma
65 medulloblastomaand ependymoma
66 months
67 months of diagnosis
68 morbidity
69 neurodevelopmental outcome
70 normal range
71 outcomes
72 percentile
73 poor rateof survival
74 post relapse
75 postsurgical therapy
76 primary chemotherapy
77 primary postsurgical therapy
78 primary therapy
79 radiation
80 radiation hadlower IQs
81 radiotherapy
82 range
83 rateof survival
84 recurrent disease
85 relapse
86 salvagetherapy
87 surgical excision
88 survival
89 survivaltime
90 term morbidity
91 therapy
92 time
93 treatment
94 trial of mechlorethamine
95 trials
96 tumors
97 vincristine
98 years
99 young children
100 yrs post relapse
101 schema:name MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children
102 schema:pagination 243-252
103 schema:productId N4827cdcbed5a47f4a303b1c441cc6314
104 Ndf2e1463885246fd83424b56c447da03
105 Nf641bef2b7884640b260746f90545533
106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000646940
107 https://doi.org/10.1023/a:1005744527443
108 schema:sdDatePublished 2022-01-01T18:08
109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
110 schema:sdPublisher N52df1b44460743248fad63a5092eed17
111 schema:url https://doi.org/10.1023/a:1005744527443
112 sgo:license sg:explorer/license/
113 sgo:sdDataset articles
114 rdf:type schema:ScholarlyArticle
115 N08207dd13f1240ea95454e4b42780d3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Vincristine
117 rdf:type schema:DefinedTerm
118 N27f45763f5a44a24a954903078b971cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Procarbazine
120 rdf:type schema:DefinedTerm
121 N2ee6cab87bc94817b64f0030a636703b schema:issueNumber 3
122 rdf:type schema:PublicationIssue
123 N40c608e5cb7444a7a2eec144197d2770 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Antineoplastic Combined Chemotherapy Protocols
125 rdf:type schema:DefinedTerm
126 N44c81835dbc94bd7a48eab57d1d517f9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Mechlorethamine
128 rdf:type schema:DefinedTerm
129 N4827cdcbed5a47f4a303b1c441cc6314 schema:name dimensions_id
130 schema:value pub.1000646940
131 rdf:type schema:PropertyValue
132 N4ab9425648ae4c60810e4bd5e561e655 rdf:first Ndb131690ce79439e95eee059d24cafeb
133 rdf:rest Nc014f2ffbc774e1eb0ba1a0d296f6653
134 N52df1b44460743248fad63a5092eed17 schema:name Springer Nature - SN SciGraph project
135 rdf:type schema:Organization
136 N57254cfcb6ee48dc9c03fa238f12d8cb rdf:first sg:person.015203521537.11
137 rdf:rest Nef1e8e228c3f432496ebc2aaa2cb4b86
138 N61d238067e0a47da9548584ab32d8206 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Cerebellar Neoplasms
140 rdf:type schema:DefinedTerm
141 N6331d787a594495a8fd69a47da63537b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Prednisone
143 rdf:type schema:DefinedTerm
144 N67bc444c5a6d441f8f643b9a7ee7d54a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Intelligence Tests
146 rdf:type schema:DefinedTerm
147 N8226d466276540f9ba47a65a30f675dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Brain Neoplasms
149 rdf:type schema:DefinedTerm
150 Na456f8a2ea2e4608bf3e8e62b70c72f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Chemotherapy, Adjuvant
152 rdf:type schema:DefinedTerm
153 Na8998ec9fdb6495b819e432f8ec12c00 rdf:first sg:person.01110645104.27
154 rdf:rest N4ab9425648ae4c60810e4bd5e561e655
155 Naf6e47ed61f84908b073e3ebf0842c60 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Female
157 rdf:type schema:DefinedTerm
158 Nba80a5f929474713bbb381781209fa08 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Male
160 rdf:type schema:DefinedTerm
161 Nbcbf067494e9477891f61e7a1ec16a31 rdf:first sg:person.013375073077.30
162 rdf:rest rdf:nil
163 Nc014f2ffbc774e1eb0ba1a0d296f6653 rdf:first sg:person.012415720762.23
164 rdf:rest N57254cfcb6ee48dc9c03fa238f12d8cb
165 Nc0f3ab3a603d49c9a7dde0d02df2ee19 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Ependymoma
167 rdf:type schema:DefinedTerm
168 Ndb131690ce79439e95eee059d24cafeb schema:affiliation grid-institutes:None
169 schema:familyName Eys
170 schema:givenName Jan van
171 rdf:type schema:Person
172 Nddd64aabe6854bb18293147c5fd96e78 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Treatment Outcome
174 rdf:type schema:DefinedTerm
175 Ndf2e1463885246fd83424b56c447da03 schema:name pubmed_id
176 schema:value 9049886
177 rdf:type schema:PropertyValue
178 Ndfe2d757403d435b81bdc5d67c5b3c8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Follow-Up Studies
180 rdf:type schema:DefinedTerm
181 Ne45d24f62fcc46519afae80e86ca5fbf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 Ne6db28a0fa3e4da3bc5caa2341b65f72 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Medulloblastoma
186 rdf:type schema:DefinedTerm
187 Ne7389cc13df044bcaa49e58a2dce6a2b schema:volumeNumber 32
188 rdf:type schema:PublicationVolume
189 Nef1e8e228c3f432496ebc2aaa2cb4b86 rdf:first sg:person.0667371236.93
190 rdf:rest Nbcbf067494e9477891f61e7a1ec16a31
191 Nf641bef2b7884640b260746f90545533 schema:name doi
192 schema:value 10.1023/a:1005744527443
193 rdf:type schema:PropertyValue
194 Nf8ef26cf59b24a84a3c5cd734b506714 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Infant
196 rdf:type schema:DefinedTerm
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
201 schema:name Oncology and Carcinogenesis
202 rdf:type schema:DefinedTerm
203 sg:grant.2467142 http://pending.schema.org/fundedItem sg:pub.10.1023/a:1005744527443
204 rdf:type schema:MonetaryGrant
205 sg:journal.1094205 schema:issn 0167-594X
206 1573-7373
207 schema:name Journal of Neuro-Oncology
208 schema:publisher Springer Nature
209 rdf:type schema:Periodical
210 sg:person.01110645104.27 schema:affiliation grid-institutes:None
211 schema:familyName Ater
212 schema:givenName Joann L.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110645104.27
214 rdf:type schema:Person
215 sg:person.012415720762.23 schema:affiliation grid-institutes:None
216 schema:familyName Woo
217 schema:givenName Shiao Y.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012415720762.23
219 rdf:type schema:Person
220 sg:person.013375073077.30 schema:affiliation grid-institutes:grid.240145.6
221 schema:familyName Bruner
222 schema:givenName Janet
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013375073077.30
224 rdf:type schema:Person
225 sg:person.015203521537.11 schema:affiliation grid-institutes:None
226 schema:familyName III
227 schema:givenName Bartlett Moore
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015203521537.11
229 rdf:type schema:Person
230 sg:person.0667371236.93 schema:affiliation grid-institutes:None
231 schema:familyName Copeland
232 schema:givenName Donna R.
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0667371236.93
234 rdf:type schema:Person
235 sg:pub.10.1007/bf00165184 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022244908
236 https://doi.org/10.1007/bf00165184
237 rdf:type schema:CreativeWork
238 grid-institutes:None schema:alternateName Clinical Radiotherapy, USA
239 The Departments of Pediatrics, USA
240 schema:name Clinical Radiotherapy, USA
241 The Departments of Pediatrics, USA
242 rdf:type schema:Organization
243 grid-institutes:grid.240145.6 schema:alternateName Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
244 schema:name Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
245 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...